Twenty-two patients (19 men) with heart failure (16 ischemic, 6 dilated cardiomyopathy; mean age of 67 +/- 6 years) in New York Heart Association classes I (2 patients), II (18 patients), and III (2 patients) under optimal therapy were strictly monitored after carvedilol supplementation. The Tei index decreased significantly from 0.87 +/- 0.17 to 0.53 +/- 0.29 (p <0.03). Conversely, the ejection fraction and transmitral Doppler flow analysis did not show significant improvement, despite a trend toward the amelioration of the ejection fraction, the E-/A-wave ratio, and atrial contribution. The Tei index could represent an earlier marker to evaluate drug-induced left ventricular function improvement in patients with heart failure and could represent a more sensitive tool to monitor left ventricular function during drug interventions.